ଟ୍ରାଷ୍ଟୁଜୁମାବ ଡେରୁକ୍ସଟେକାନ

ଟ୍ରାଷ୍ଟୁଜୁମାବ ଡେରୁକ୍ସଟେକାନ
Monoclonal antibody
Type	Whole antibody
Source	Humanized
Target	HER2
Clinical data
Trade names	Enhertu
Synonyms	DS-8201a, fam-trastuzumab deruxtecan-nxki
AHFS/Drugs.com	monograph
data	US DailyMed: Trastuzumab_deruxtecan;
Pregnancy; category	AU: D ; ;
Routes of; administration	Intravenous
Legal status
Legal status	AU: S4 (Prescription only) ; US: ℞-only ; EU: Rx-only ; Rx-only;
Chemical and physical data
Formula	C6460H9972N1724O2014S44.(C52H57F1N9O13)8

ଟ୍ରାଷ୍ଟୁଜୁମାବ ଡେରୁକ୍ସଟେକାନ, ଏକ ବେପାର ନାମ ଏନହେର୍ଟୁ ହେଉଛି ସ୍ତନ କର୍କଟ ଏବଂ ଗ୍ୟାଷ୍ଟ୍ରିକ୍ କିମ୍ବା ଗ୍ୟାଷ୍ଟ୍ରୋଏସୋଫେଜ୍ ଆଡେନୋକାର୍କିନୋମା ରୋଗମାନଙ୍କର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହେଉଥିବା ଏକ ଔଷଧ ।^[୫] ^[୬] ନିର୍ଦ୍ଦିଷ୍ଟ ଭାବରେ ଏହା ଏଚଇଆର୨ (HER2) ସକରାତ୍ମକ ରୋଗ ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୫] ^[୬] ଏହା ଏକ ଶିରାରେ ଧୀରେ ଧୀରେ ଇଞ୍ଜେକସନ ଆକାରରେ ଦିଆଯାଏ ।^[୨]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଅଇ, ଥକାପଣ, କେଶ ଝଡ଼ିବା, କୋଷ୍ଠକାଠିନ୍ୟ, ସ୍ୱଳ୍ପ ଲାଲ ରକ୍ତ କଣିକା, ସ୍ୱଳ୍ପ ଶ୍ୱେତ ରକ୍ତ କଣିକା, କମ୍ ପ୍ଲାଟେଲେଟ୍ ଏବଂ ମୁଣ୍ଡବିନ୍ଧା ହୋଇପାରେ ।^[୨] ଅନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ କମ ପୋଟାସିୟମ୍, ଅନିୟମିତ ହୃତ୍ ସ୍ପନ୍ଦନ, ଇଣ୍ଟରଷ୍ଟିସିଆଲ୍ ଫୁସଫୁସ ରୋଗ ଏବଂ ଯକୃତ ସମସ୍ୟା ହୋଇପାରେ ।^[୨] ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର ଶିଶୁର କ୍ଷତି କରିପାରେ ।^[୧] ଏଥିରେ ମୋନୋକ୍ଲୋନାଲ ଆଣ୍ଟିବଡି ଟ୍ରାଷ୍ଟୁଜୁମାବ ସ‌ହିତ ଟପୋଏସୋମେରେଜ ୧ ଇନହିବିଟର ଡେରକ୍ସଟେକାନ ସଂଯୁକ୍ତ ହୋଇଥାଏ ।^[୨] ଏପିଡର୍ମାଲ୍ ଅଭିବୃଦ୍ଧି ଫ୍ୟାକ୍ଟର୍ ରିସେପ୍ଟର ୨ (HER2 / neu) ସହିତ ଟ୍ରାଷ୍ଟୁଜୁମାବ ବାନ୍ଧୁଥିବାବେଳେ ଡେରକ୍ସଟେକାନ୍ ଡିଏନ୍ଏ ତିଆରି କରିବାର ଜୀବକୋଷର କ୍ଷମତାକୁ ଅବରୋଧ କରିଥାଏ ।^[୨]

୨୦୧୯ ମସିହାରେ ଡାକ୍ତରୀ ବ୍ୟବହାର ପାଇଁ ଟ୍ରାଷ୍ଟୁଜୁମାବ ଡେରକ୍ସଟେକାନ ଆମେରିକାରେ, ^[୫] ୨୦୨୦ ମସିହାରେ ଜାପାନରେ, ^[୭] ୟୁରୋପ ଏବଂ ଅଷ୍ଟ୍ରେଲିଆରେ ୨୦୨୧ରେ ଅନୁମୋଦିତ ହୋଇଥିଲା । ^[୨] ^[୧] ଯୁକ୍ତରାଜ୍ୟରେ ୧୦୦ ମିଗ୍ରା ପାଇଁ ୧୪୫୦ ପାଉଣ୍ଡ ଖର୍ଚ୍ଚ ହୁଏ ।^[୮] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ପରିମାଣ ନିମନାତେ ପ୍ରାୟ ୨୫୦୦ ଡଲାର ଖର୍ଚ୍ଚ ହୁଏ ।^[୯]

ଆଧାର

↑ ^୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ "Enhertu". Therapeutic Goods Administration (TGA). 18 October 2021. Archived from the original on 23 October 2021. Retrieved 22 October 2021.
↑ ^୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ ^୨.୪ ^୨.୫ ^୨.୬ "Enhertu EPAR". European Medicines Agency (EMA). 9 December 2020. Archived from the original on 23 March 2021. Retrieved 31 March 2021.
↑ "Enhertu- fam-trastuzumab deruxtecan-nxki injection, powder, lyophilized, for solution". DailyMed. Archived from the original on 22 January 2021. Retrieved 15 January 2021.
↑ "Enhertu approved in the EU for the treatment of HER2-positive metastatic breast cancer" (Press release). AstraZeneca. 20 January 2021. Archived from the original on 20 January 2021. Retrieved 21 January 2021.
↑ ^୫.୦ ^୫.୧ ^୫.୨ "Fam-Trastuzumab Deruxtecan-nxki Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 27 December 2021. Retrieved 10 December 2021.
↑ ^୬.୦ ^୬.୧ "FDA approves fam-trastuzumab deruxtecan-nxki for HER2-positive gastric adenocarcinomas". U.S. Food and Drug Administration (FDA). 15 January 2021. Archived from the original on 15 January 2021. Retrieved 15 January 2021.
↑ "Enhertu Approved in Japan for Treatment of Patients with HER2 Positive Unresectable or Metastatic Breast Cancer" (Press release). Daiichi Sankyo. 25 March 2020. Archived from the original on 28 January 2021. Retrieved 21 January 2021.
↑ "Trastuzumab deruxtecan". SPS - Specialist Pharmacy Service. 23 December 2018. Archived from the original on 11 December 2021. Retrieved 10 December 2021.
↑ "Enhertu Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 26 January 2021. Retrieved 10 December 2021.

[TGA2021-1] ୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ "Enhertu". Therapeutic Goods Administration (TGA). 18 October 2021. Archived from the original on 23 October 2021. Retrieved 22 October 2021.

[EPAR2021-2] ୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ ^୨.୪ ^୨.୫ ^୨.୬ "Enhertu EPAR". European Medicines Agency (EMA). 9 December 2020. Archived from the original on 23 March 2021. Retrieved 31 March 2021.

[3] "Enhertu- fam-trastuzumab deruxtecan-nxki injection, powder, lyophilized, for solution". DailyMed. Archived from the original on 22 January 2021. Retrieved 15 January 2021.

[AstraZeneca_PR_20210120-4] "Enhertu approved in the EU for the treatment of HER2-positive metastatic breast cancer" (Press release). AstraZeneca. 20 January 2021. Archived from the original on 20 January 2021. Retrieved 21 January 2021.

[AHFS2021-5] ୫.୦ ^୫.୧ ^୫.୨ "Fam-Trastuzumab Deruxtecan-nxki Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 27 December 2021. Retrieved 10 December 2021.

[FDA2021Gast-6] ୬.୦ ^୬.୧ "FDA approves fam-trastuzumab deruxtecan-nxki for HER2-positive gastric adenocarcinomas". U.S. Food and Drug Administration (FDA). 15 January 2021. Archived from the original on 15 January 2021. Retrieved 15 January 2021.

[7] "Enhertu Approved in Japan for Treatment of Patients with HER2 Positive Unresectable or Metastatic Breast Cancer" (Press release). Daiichi Sankyo. 25 March 2020. Archived from the original on 28 January 2021. Retrieved 21 January 2021.

[SP2021-8] "Trastuzumab deruxtecan". SPS - Specialist Pharmacy Service. 23 December 2018. Archived from the original on 11 December 2021. Retrieved 10 December 2021.

[9] "Enhertu Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 26 January 2021. Retrieved 10 December 2021.

[୫]

[୬]

[୨]

[୧]

[୩]

[୪]

[୭]

[୮]

[୯]